The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis
- 1 August 2015
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 109 (2) , 378-388
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatmentDiabetology & Metabolic Syndrome, 2013
- Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory studyCardiovascular Diabetology, 2013
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyInternational Journal Of Clinical Practice, 2010
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- The "number needed to treat" turns 20 -- and continues to be used and misusedCanadian Medical Association Journal, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trialDiabetes, Obesity and Metabolism, 2007
- Adjusting for publication bias in the presence of heterogeneityStatistics in Medicine, 2003